OPEN ACCESS Freely available online

Journal of Hematology & Thromboembolic Diseases

Short Communication

Unfolded Protein Response (UPR) Signaling Pathways: A Novel Approach for Mitigating Erythroblast Apoptosis in β-Thalassemia

Hiroyuki Ishikawa*

Department of Dermatology, Bar-Ilan University, Ramat Gan, Israel

DESCRIPTION

β-Thalassemia is a hereditary hematological disorder characterized by reduced or absent synthesis of β-globin chains, leading to ineffective erythropoiesis and hemolysis. Erythroblast apoptosis contributes significantly to the pathophysiology of β-thalassemia. Unfolded Protein Response (UPR) signaling has emerged as a critical pathway in cellular homeostasis, particularly in conditions of Endoplasmic Reticulum (ER) stress. This review explores the potential of targeting UPR signaling pathways to reduce erythroblast apoptosis in β-thalassemia. We summarize the current understanding of UPR activation and its implications in β-thalassemia pathogenesis, focusing on its role in modulating erythroid cell survival and differentiation. Furthermore, we discuss recent advances in UPR-targeted therapeutic strategies and their potential application in ameliorating β-thalassemia-associated erythroblast apoptosis. Overall, targeting UPR signaling pathways holds promise as a novel therapeutic approach to mitigate erythroblast apoptosis and improve the management of β-thalassemia.

β-thalassemia represents a group of inherited hemoglobinopathies characterized by reduced or absent synthesis of β-globin chains, resulting in imbalanced α/β-globin chain production, ineffective erythropoiesis, and hemolytic anemia [1]. The disease spectrum ranges from asymptomatic carriers to severe transfusion-dependent phenotypes, posing a significant global health burden particularly in regions with high prevalence of carriers [2]. Despite advancements in supportive care, including regular blood transfusions and iron chelation therapy, the management of β-thalassemia remains challenging, emphasizing the need for novel therapeutic strategies targeting its underlying pathophysiology.

Erythroblast apoptosis, a process of programmed cell death, plays a pivotal role in the pathogenesis of β-thalassemia [3]. Excessive apoptosis within the erythroid lineage contributes to ineffective erythropoiesis, exacerbating anemia and ultimately leading to bone marrow failure [4]. Thus, strategies aimed at mitigating erythroblast apoptosis represent a promising therapeutic avenue in β-thalassemia management.

Unfolded Protein Response (UPR) signaling in cellular homeostasis

The Endoplasmic Reticulum (ER) is a central organelle involved in protein synthesis, folding, and post-translational modifications. Perturbations in ER function, such as the accumulation of misfolded or unfolded proteins, trigger a conserved cellular stress response known as the Unfolded Protein Response (UPR) [5]. The UPR aims to restore ER homeostasis by attenuating global protein synthesis, enhancing protein folding capacity, and promoting the clearance of misfolded proteins [6]. The UPR is mediated by three main transmembrane sensors located on the ER membrane: Inositol-Requiring Enzyme 1 (IRE1), Activating Transcription Factor 6 (ATF6), and Protein Kinase R-Like ER Kinase (PERK) [7]. Under conditions of ER stress, these sensors are activated, initiating downstream signaling cascades to alleviate stress and promote cell survival. However, prolonged or severe ER stress can lead to apoptosis, highlighting the dual role of UPR signaling in cellular fate determination.

Implications of UPR signaling in β-thalassemia pathogenesis

Growing evidence suggests a crucial involvement of UPR signaling in the pathophysiology of β-thalassemia. The dysregulation of globin chain synthesis in β-thalassemia leads to the accumulation of unfolded globin chains within the ER, triggering ER stress and activating the UPR [8]. Studies have demonstrated increased expression of UPR-associated genes in β-thalassemic erythroid precursors, indicative of UPR activation in response to aberrant globin chain synthesis [9]. However, sustained UPR activation may exacerbate ER stress and promote erythroblast apoptosis, contributing to ineffective erythropoiesis in β-thalassemia.

Correspondence to: Hiroyuki Ishikawa, Department of Dermatology, Bar-Ilan University, Ramat Gan, Israel, E-mail: Ishikawa@hiroyuki

Received: 01-Mar-2024, Manuscript No JHTD-24-30680; **Editor assigned:** 04-Mar-2024, PreQC No. JHTD-24-30680 (PQ); **Reviewed:** 18-Mar-2024, QC No. JHTD-24-30680; **Revised:** 25-Mar-2024, Manuscript No. JHTD-24-30680 (R); **Published:** 01-Apr-2024, DOI: 10.35248/2329-8790.24.12.596.

Citation: Ishikawa H (2024) Unfolded Protein Response (UPR) Signaling Pathways: A Novel Approach for Mitigating Erythroblast Apoptosis in β-Thalassemia. J Hematol Thrombo Dis.12:596.

Targeting UPR signaling to reduce erythroblast apoptosis in β-thalassemia

Given the intricate interplay between UPR signaling and erythroblast apoptosis in β-thalassemia pathogenesis, therapeutic interventions aimed at modulating UPR activity hold therapeutic potential. Several pharmacological agents targeting key components of the UPR pathway have shown potenial in preclinical models of β-thalassemia. For instance, small molecule inhibitors of PERK or IRE1 have been shown to attenuate ER stress and reduce erythroblast apoptosis in β-thalassemic mice, highlighting the feasibility of UPR-targeted strategies in ameliorating disease manifestations [10]. Moreover, gene editing technologies, such as CRISPR-Cas9, offer the possibility of correcting the underlying genetic defects in β-thalassemia, thereby alleviating ER stress and UPR activation.

CONCLUSION

In conclusion, targeting UPR signaling pathways represents a promising therapeutic approach to reduce erythroblast apoptosis and ameliorate the pathophysiology of β-thalassemia. Further elucidation of the molecular mechanisms governing UPR activation in β-thalassemic erythropoiesis is warranted to identify novel therapeutic targets and refine treatment strategies. Additionally, clinical translation of UPR-targeted therapies requires rigorous evaluation in human subjects to ensure efficacy, safety, and long-term outcomes. Ultimately, the integration of UPR modulation into existing therapeutic regimens may offer new avenues for personalized medicine in β-thalassemia management, improving patient outcomes and quality of life.

REFERENCES

1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics-2022 update: A report from the American Heart Association. Circulation. 2022;145(8):e153-e639.
2. Bos D, Arshi B, van den Bouwhuijsen QJ, Ikram MK, Selwaness M, Vernooij MW, et al. Atherosclerotic carotid plaque composition and incident stroke and coronary events. J Am Coll Cardiol. 2021;77(11):1426-1435.
3. Wang X, Li W, Song F, Wang L, Fu Q, Cao S, et al. Carotid atherosclerosis detected by ultrasonography: A national cross-sectional study. J Am Heart Assoc. 2018;7(8):e008701.
4. Fu J, Deng Y, Ma Y, Man S, Yang X, Yu C, et al. National and provincial-level prevalence and risk factors of carotid atherosclerosis in Chinese adults. JAMA Netw Open. 2024;7(1):e2351225.
5. Owusu J, Barrett E. Early microvascular dysfunction: Is the vasa vasorum a "missing link" in insulin resistance and atherosclerosis. Int J Mol Sci. 2021;22(14):7574.
6. Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: A systematic review, meta-analysis, and modelling study. Lancet Glob Health. 2020;8(5):e721-e729.
7. Garg PK, Bhatia HS, Allen TS, Grainger T, Pouncey AL, Dichek D, et al. Assessment of subclinical atherosclerosis in asymptomatic people *in vivo*: Measurements suitable for biomarker and Mendelian randomization studies. Arterioscler Thromb Vasc Biol. 2024;44(1):24-47.
8. Camps-Vilaro A, Subirana I, Ramos R, Cainzos-Achirica M, Tizon-Marcos H, Fito M, et al. five-year changes in inflammatory, metabolic, and oxidative biomarkers and 10-year cardiovascular disease incidence: The REGICOR cohort study. Int J Mol Sci. 2023;24(9):7934.
9. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: The San Antonio heart study. Diabetes care. 2002;25(7):1177-1184.
10. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance *in vivo*: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1):E15-E26.